Podcasts about biomarkers

BUFFALO, NY — April 21, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 14, 2025, titled “Effects of a natural ingredients-based intervention targeting the hallmarks of aging on epigenetic clocks, physical function, and body composition: a single-arm clinical trial.” A team of researchers, led by first authors Natalia Carreras-Gallo and Rita Dargham, and corresponding author Varun B. Dwaraka from TruDiagnostic, studied how a natural anti-aging supplement called the Cel System might influence the aging process. They found that participants who took the supplement for one year showed a reduction in biological age, along with improved muscle strength and body composition. The study highlights the potential of lifestyle and nutritional supplements to support healthy aging. “The Cel System supplement range was formulated to target pathways associated with the Hallmarks of Aging when combining Cel1, Cel2, and Cel3 formulas.” Cel System is a natural supplement made from a mix of plant compounds, vitamins, and antioxidants designed to target the biological mechanisms associated with aging. Over the course of a year, 51 adults between the ages of 54 and 84 participated in the clinical trial. The group included 26 men and 25 women. Researchers tracked changes in biological age using DNA-based tests known as epigenetic clocks, along with physical performance and body composition metrics. Participants were also encouraged to walk for 10 minutes and practice mindfulness for five minutes daily. Results showed that participants experienced improvements in grip strength, lower body mobility, and reductions in body weight, waist circumference, and body mass index. These physical gains were supported by slower biological aging, as measured by multiple epigenetic clocks. In addition, the supplement appeared to reduce stem cell turnover, a key marker of aging at the cellular level. The study also reported changes in immune cell composition, suggesting that the supplement may help regulate immune function as people age. Biomarkers associated with liver function also shifted, pointing to potential improvements in organ health. However, levels of inflammation markers did not significantly change. Analysis of methylation chemical marks on DNA revealed that the supplement influenced gene activity related to stress response, brain function, and cell communication. These molecular-level changes may help explain the broader benefits seen in physical and biological aging measures. Although this was a pilot study without a control group, the findings suggest that the Cel System supplement shows potential for reducing signs of aging and improving overall health. The authors suggest future randomized controlled trials with larger sample sizes to confirm these results and explore the supplement's long-term effects on longevity. This study adds to growing evidence that targeted natural supplements may slow biological aging and extend healthspan. By combining epigenetic analysis with real-world health data, the findings offer new insight into how nutraceuticals, like Cel System, could promote long-term health and resilience. Paper: DOI: https://doi.org/10.18632/aging.206221 Corresponding author: Varun B. Dwaraka – varun.dwaraka@trudiagnostic.com Keywords: aging, epigenetic age change, physiological age change, epigenetic biomarker proxies, hallmarks of aging, nutraceutical longevity interventions To learn more about the journal, please visit our website at www.Aging-US.com​​ and connect with us on social media at: Facebook - www.facebook.com/AgingUS/ X - twitter.com/AgingJrnl Instagram - www.instagram.com/agingjrnl/ YouTube - www.youtube.com/@AgingJournal LinkedIn - www.linkedin.com/company/aging/ Pinterest - www.pinterest.com/AgingUS/ Spotify - open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Scientific discovery happens in the lab—but it starts with curiosity and determination. In this episode of Absolute Gene-ius, we welcome Valeria Rangel, a PhD candidate at the University of California Irvine, who shares her research on acute lymphoblastic leukemia and the innovative ways digital PCR is helping uncover genetic patterns linked to cancer in Hispanic populations.Val's work focuses on Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia, a rare and aggressive form of cancer. She explains how her lab uses digital PCR to detect mutations with high precision, identify risk factors in certain populations, and even validate findings using CRISPR-Cas9 gene editing. Through her research, Val sheds light on the role of SNPs, methylation patterns, and translocations in leukemia progression—demonstrating how digital PCR is transforming the way we approach cancer research.Beyond the science, Val takes us on her personal journey, from struggling to break into research due to financial barriers to finding her passion in oncology. In this episode's Career Corner, she shares valuable advice for aspiring scientists, tips for landing research opportunities, and some of her most hilarious and humbling lab moments (yes, she has broken multiple pipettes).Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Want to become a FEARLESS entrepreneur and leader? Go here: https://books.ryanhanley.com/ Hormones influence everything—energy, focus, performance. Optimizing testosterone can be the shift from surviving to truly thriving. Jay Campbell is a 5x international best-selling author, men's physique champion, and the Owner and Co-Founder of BioLongevity Labs. Widely recognized as a leading expert on hormonal optimization, therapeutic peptides, and biohacking for health and performance, Jay is on a mission to help individuals break free from the failing "sick care" system and take control of their health. Ryan relates his personal experience of hormonal deficiency and the profound impact of optimizing testosterone levels on his energy, mental clarity, and overall performance. Jay Campbell emphasizes the importance of taking ownership of one's health, given that many traditional doctors may lack the necessary understanding of therapeutic hormones and the endocrine system. This episode explores modern health challenges and solutions, including misinformation, sedentary lifestyles, and GLP-1 agonists. It emphasizes the dangers of quick fixes and the importance of spiritual and mental clarity.

Want to become a FEARLESS entrepreneur and leader? Go here: https://books.ryanhanley.com/ Hormones influence everything—energy, focus, performance. Optimizing testosterone can be the shift from surviving to truly thriving. Jay Campbell is a 5x international best-selling author, men's physique champion, and the Owner and Co-Founder of BioLongevity Labs. Widely recognized as a leading expert on hormonal optimization, therapeutic peptides, and biohacking for health and performance, Jay is on a mission to help individuals break free from the failing "sick care" system and take control of their health. Ryan relates his personal experience of hormonal deficiency and the profound impact of optimizing testosterone levels on his energy, mental clarity, and overall performance. Jay Campbell emphasizes the importance of taking ownership of one's health, given that many traditional doctors may lack the necessary understanding of therapeutic hormones and the endocrine system. This episode explores modern health challenges and solutions, including misinformation, sedentary lifestyles, and GLP-1 agonists. It emphasizes the dangers of quick fixes and the importance of spiritual and mental clarity.

Callum and Alyssa are joined by Professor Malcolm Richardson to talk about all things fungal diagnostics.In this, part 1 of 2 on diagnostics we discuss the use of biomarkers such as beta-D-Glucan and galactomannan, as well as serology and molecular techniques.Notes for this episode can be found: here.Send us a textSupport the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

In "Episode 1" of the series "Present and future of diagnostics in prostate cancer," Assoc. Prof. Juan Gomez Rivas (ES) and Dr. Elena Castro (ES) explore the importance of genomics and biomarkers in localised prostate cancer.The episode reviews why these diagnostic tools are pivotal in the changing landscape of prostate cancer, offering a deeper understanding of their current and future role in patient care.Assoc. Prof. Gomez Rivas and Dr. Castro discuss how these advancements in molecular profiling and biomarker testing can revolutionise the diagnosis and management of prostate cancer. Their conversation highlights the evolving nature of prostate cancer diagnosis, offering valuable perspectives on how genomics and biomarkers are shaping the future of personalised treatment strategies.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Updates in classification, evaluation, and treatment Become dexterous with dementia management! We're talking with Dr. Anna Chodos about cognitive domains, diagnostic criteria, patient and caregiver resources, new antibody therapies, and brain health plans!  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Rapid fire questions The Terminology of Neurocognitive Disorders Cognitive Domains: A Comprehensive Approach Physical Examination Insights Medical Workup for Dementia Imaging and Biomarkers in Dementia Diagnosis Referral Considerations for Dementia Patients Understanding Dementia Stages and Prognosis Implementing Brain Health Plans Medications for Dementia Management Controversies in Monoclonal Antibody Therapies The Importance of Early Detection and Planning Outro Credits Producers, Writers and Show Notes: Leah Witt, MD and Margaret Heller, MD Infographic and Cover Art: Leah Witt, MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Anna Chodos, MD Disclosures Dr. Chodos received remuneration from Novo Nordisk for participating in a task force looking at the feasibility of incorporating biomarkers for Alzheimer's disease into primary care. The financial relationship has ended. The Curbsiders report no relevant financial disclosures.  The production of this episode was supported by the Penn Geriatrics AGE-SMART Geriatric Workforce Enhancement Grant. This podcast content is solely the responsibility of the authors and does not necessarily represent the official views of the Health Resources and Services Administration or the U.S. Department of Health and Human Services. Sponsor: Locumstory Locumstory.com is simply a free, unbiased educational resource about locum tenens.  Sponsor: Grammarly  Download Grammarly for free at Grammarly.com/PODCAST Sponsor: Continuing Education Company Special offer for Curbsiders listeners: Save 30% on all online courses and live webcasts with promo code CURB30. Visit www.CMEmeeting.org/curbsiders to explore all offerings and claim your discount. Whether live, online, or on-demand, Continuing Education Company makes earning CME easy and rewarding.

There's a reason your skin might feel like it aged five years in the last one. Stress, toxins, tech overload, hormone shifts, you name it. And those “miracle” lasers at your local med spa? Some might be melting fat off your face. Literally. Rachel Varga is here to clean up the chaos. This double board-certified aesthetic nurse specialist has done over 20,000 rejuvenation procedures, taught clinics worldwide, and spent years researching how to age slower—and look more radiant while you do it. We're talking collagen breakdown, lab tests for biological skin age, what inflammation really does to your face, and how to dodge gimmicky med spa treatments that waste your time and money.   "We forget that when we have more energy to go through life, guess what? Our skin is also gonna have more energy to be more healthy and radiant as well.” ~ Rachel Varga   In This Episode:  - Rachel's background in aesthetics and skin rejuvenation - Biomarkers for tracking skin aging - Blood sugar's devastating impact on collagen - Best treatments available in med spa - Collagen degradation biomarkers - Red light therapy for skincare - Broadband light therapy that reverses skin age - Med spa treatments and industry trends: what you should know - Rachel's new skincare line & why it's different - Toxins in beauty products destroy hormones - C60 for topical antioxidant protection - Fragrances and their effect on skin For more information, visit https://www.myersdetox.com    Heavy Metals Quiz: Find out your toxicity score and receive a free video series on detoxification. Visit https://heavymetalsquiz.com    Resources Mentioned: Bon Charge Red Light Face Mask: Get 15% off with code WENDY at https://boncharge.com    About Rachel Varga: Rachel is a double board-certified aesthetic nurse specialist, published researcher, and host of the School of Radiance podcast. She's performed over 20,000 rejuvenation procedures and trained professionals worldwide. Known for her gentle touch and natural-looking results, Rachel blends Western skincare, functional medicine, and biohacking to help you look and feel your best—without the fluff, hype, or damage.   Use code DRWENDYMYERS for 15% off a one-on-one skin consultation with Rachel Varga. Shop her non-toxic, med-grade skincare line at https://theschoolofradiance.com.    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

How can we reduce the elevated risk of suicidality for those struggling with an eating disorder? Join us as we explore the critical connection between eating disorders, suicidality, and the malnourished brain with Dr. James Greenblatt MD, a distinguished expert, best-selling author, and nationally recognized leader in the field of Functional and Integrative Psychiatry. With over three decades of experience, Dr. Greenblatt offers insights into how measuring frequently overlooked biomarkers and replenishing specific nutritional deficiencies can target suicidality and other mental health symptoms at their biological roots.   If you enjoy our show, please rate, review, subscribe, and tell your friends and colleagues!   Interested in being a guest on All Bodies. All Foods.? Email podcast@renfrewcenter.com for a chance to be featured.   All Bodies. All Foods. is a podcast by The Renfrew Center. Visit us at: https://renfrewcenter.com/

Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi Velcheti: Hello. I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health.  The management of small cell lung cancer has rapidly evolved over the past few decades, and today, molecular testing and biomarker testing for lung cancer are absolutely critical in terms of designing treatment options for our patients with metastatic non-small cell lung cancer. Today, I'm delighted to be joined by Dr. Charu Aggarwal for a discussion on ctDNA (circulating tumor DNA) and the role of ctDNA in lung cancer management. Dr. Aggarwal is the Leslye Heisler Professor of Lung Cancer Excellence and section chief of thoracic and head and neck oncology at University of Pennsylvania Abramson Cancer Center.  You'll find our full disclosures in the transcript of that episode.  Dr. Agrawal, it's great to have you on the podcast today. Thank you for being here. Dr. Charu Aggarwal: Thank you for having me. Dr. Vamsi Velcheti: Let's start off with setting the stage for ctDNA technology. These technologies have rapidly evolved from experimental conceptual stage to essential clinical tools for day-to-day clinical practice. Could you briefly discuss how recent advancements in ctDNA technologies are shaping our approach to precision medicine, especially in lung cancer? Dr. Charu Aggarwal: Absolutely. And you know, I think we need to just level set a little bit. What exactly is circulating tumor DNA? This is a way to assess exactly that. Every tumor sheds little pieces of tumor-derived DNA into the bloodstream, and this occurs in a variety of solid tumors. But now we have the technology to be able to derive this DNA that's actually being shed from the tumor into the bloodstream, these minute fragments of DNA, take them out, amplify them and sequence them with a variety of different mechanisms. They can be DNA sequencing alone, they can be DNA and RNA sequencing, they can be whole transcriptome sequencing. The technology, as you rightly pointed out, Dr. Velcheti, has significantly improved from just being able to look at circulating tumor DNA to now being able to amplify it, sequence it, and use it to offer personalized therapy. I think lung cancer is definitely the poster child for such an approach as we have a lot of data that has shown clinical utility and validity of being able to use circulating tumor DNA next-generation gene sequencing to guide therapy. Dr. Vamsi Velcheti: There have been so many technological leaps. It's really impressive how far we've come to advance these sequencing platforms. Recent advances with AI and machine learning are also playing important roles in interpreting ctDNA data. How are these computational advances really enhancing clinical decision-making in day-to-day clinical practice? Dr. Charu Aggarwal: I think while we have firmly established the role of ctDNA in the management of patients with metastatic lung cancer, some of the approaches that you talked about are still experimental. So let me backtrack a little bit and set the stage for how we use ctDNA in clinical practice right now. I think most patients, when they come in with a new diagnosis of stage IV lung cancer, we want to test for biomarkers. And this should actually be the established standard. Now included in the NCCN guidelines and actually also international guidelines, is to consider using blood-based testing or plasma-based testing to look for biomarkers, not just tissue-based testing which had been our historical standard, but to use these plasma guided approaches to identify the seven to nine biomarkers that may be truly implicated in either first- or second-line therapy that are called as your immediately actionable mutations.  What you're talking about is AI computational methods. I think there's a lot of excitement about how we can use genomic signatures that are derived from either tissue or ctDNA-based biomarker testing, combine it with radiomic features, combine it with histologic features, look at H & E patterns, use AI algorithmic learning to be able to actually predict recurrence scores, or can we actually come up with predictive signatures that may be extremely helpful?  So, I think some of the techniques and technologies that you're talking about are incoming. They are provocative. I think they're very exciting, but very early. Dr. Vamsi Velcheti: I think it's really amazing how many advances we have with these platforms. You know, the challenge really is the significant gap in terms of uptake of molecular testing. Even today, in 2025, there are significant gaps in terms of all metastatic lung cancer patients being tested for all biomarkers.  So, why do you think there's such a challenge in testing patients with lung cancer? In most academic practices, we try to achieve 100% testing for all our patients, but we know from recent studies that that's not the case across the country. What do you think the gaps are? Dr. Charu Aggarwal: Biomarker testing is so essential, like you pointed out, for us to be able to guide the right therapy for our patients. And we see this in our practice every day as you and I see patients with lung cancer, that a large proportion of our patients either don't get tested or they start therapy before their test results come back. So, I think this is a real problem.  However, to add some optimism to this problem, I do think that we are making a move in the right direction. So, four or five years ago, there was a lot of data being presented at national meetings, including ones from the American Society of Clinical Oncology, where we saw that, nationally, the rates of biomarker testing were probably in the rate of 40 to 50%. However, now with the availability of both tissue and plasma, I do think that the rates of biomarker testing are increasing. And if you were to survey a sample or even perform retrospective data research, I believe that the number is closer to 70% of all patients with metastatic non-small cell lung cancer.  And you know, you asked why is it not 100%? I think there are many reasons. I think the number one reason is tissue availability. Many times, the biopsies are small, or the tumor is very necrotic. So, either the tissue quantity itself is small, or the tissue quantity is insufficient to perform gene sequencing. And that's exactly where plasma comes in. When you don't have tissue availability, we have shown, as have others, that you can use plasma effectively to increase the proportion of patients who are not only tested but also receive the right therapy. I think there are also other barriers, including inertia. You know, I think this is both patient and physician inertia, where patients want to get started quickly, they don't want to wait. Physicians are very busy and sometimes want to be able to deliver treatment as soon as possible. We have seen there are some institutional barriers. Not every institution has in-house gene sequencing testing. So how do you really operationalize, send out these tests in a fast, efficient manner so that you get results back? Is it a pathologist who sends out the test? Is it the medical oncologist? Is it the pulmonologist or the interventionalist? I think there is this need to develop reflex testing mechanisms which some institutions do really well and some don't. And then finally, there are financial implications as well. How do we do this in a most cost-efficient fashion?  So there are many barriers, but I'm happy to say that we are making a move in the right direction as we are understanding that it's important to do it, it's easy to do it maybe with a value add of plasma, and finally, as you said, you know, as these technologies become more available, they're actually getting more cost-effective. Dr. Vamsi Velcheti: Dr. Aggarwal, you've been at the cutting edge of these advanced platforms and testing. So, what do you do in UPenn? How do you handle all these barriers and what is your workflow for patients in University of Pennsylvania? Dr. Charu Aggarwal: One of the things that I mentioned to you was there may be institutional barriers when it comes to gene sequencing. So, we actually, several years ago now, instituted a very robust reflex testing paradigm where almost all of our patients, regardless of stage, with a non-squamous non-small cell lung cancer diagnosis, would automatically be reflexively sent to our molecular pathology lab where they would get gene sequencing both for the DNA as well as with an RNA fusion-based platform. And the reason we did this was because we wanted to expedite and reduce the turnaround time. We also wanted to ensure that we were not just doing DNA testing, which I think is really important for our listeners here. There are many fusions as well as certain skipping mutations like MET exon 14 that may be missed on DNA testing alone. So, it's really incredibly important to run both DNA and RNA samples.  So, we do this routinely, and based on our research and others, what we also do routinely is that we send concurrent tissue and liquid biopsies or plasma MGS testing upon initial diagnosis. For example, if a patient comes in with a diagnosis of stage IV non-small cell lung cancer, their tissue might already be at my molecular pathology lab based on the reflex mechanism that I just described to you. But upon their initial meeting with me, we will send off plasma. And I will tell you this, that Penn is not just one institution, right? We have a large network of sites. And as part of my research, one of the things that we wanted to do was implement wide scale means to improve biomarker testing. And we have done this with the use of technology like you mentioned, Dr. Velcheti: How can we actually use AI? How can we leverage our electronic medical record to identify these patients? So, we have a nudge-based mechanism which actually facilitates the pending of orders for biomarker testing for patients with new diagnosis of metastatic non-small cell lung cancer. And we are looking at our rates of biomarker testing but also rates of completion of biomarker testing before first-line therapy started. So many of our participating sites are clusters for our randomized control trial to increase molecular testing. And I'm really excited about the fact that we're able to implement it not just at our main satellite, downtown Penn Hospital, but also across our community. Dr. Vamsi Velcheti: I think that's great. Thank you so much for those insights, Dr. Aggarwal. I think it's so important because having the best technology is just not enough. I think implementation science is actually a real thing. And I think we need to all learn from each other, advance these things.  So, I want to ask you about the new emerging paradigm in terms of using ctDNA. Of course, in the metastatic setting, we've been using ctDNA for molecular profiling for a while now. But the recent data around monitoring early-stage disease, especially post-operative monitoring, is an exciting area. There are a lot of opportunities there. Could you please talk us through the emerging data in lung cancer and how do we incorporate ctDNA-based monitoring MRD or should we even do that right now? Is the data ripe enough for us to kind of deploy this in a clinical setting? Dr. Charu Aggarwal: I think using ctDNA in the early-stage setting is our next frontier in lung cancer. I think naturally we have been able to successfully deploy this in the stage 4 setting. It made a meaningful difference in the lives of our patients, and we are a little bit behind the A ball in terms of how MRD is used in lung cancer. Because, you know, colorectal cancer has already done large-randomized trials based on ctDNA and MRD. It's routinely used in hematological malignancy. So, it makes sense that we should start to use it.  However, when I say this, I say this with excitement, but also a little bit of gentle caution saying that we actually don't quite have the prospective randomized data just yet on how to deploy. Yes, intuitively we would say that if you detect ctDNA and MRD, that patient is at higher risk. So, we identify that, but we actually don't know what to do with the second part of that information once you identify a patient with high risk. Are there other techniques that we can then come in with or other drugs that we can come in with to modify that risk? And that's the thing that I think we don't have right now. The other thing that we don't have right now is the timing of the assay, when to use it. Is it to be tested in the pre-op setting? Is the post-op test the best timing, or is it monitoring and dynamics of ctDNA that are most important? And the third thing I will say in terms of precautionary cause is that we don't know which test just yet. There are actually a few commercially available tests out in the market right now. We know about them and I'm sure our community colleagues know about them. Some of them even have Medicare approval. However, many of these tests are currently tissue informed. We don't have tissue uninformed tests. And what does that mean? Tissue uninformed means that you actually take a piece of tumor tissue, you sequence that tumor and based on the gene profile of that tumor, you actually design a panel that can then be used to track the mutations in the blood-based pack. This requires, as the name implies, a tumor. So can this be used in the pre-op setting is a large question. Because coming back to the idea of tissue availability, you and I both know that when we get FNAS and we use it for PDL-1 testing and we use it for gene sequencing, there often isn't enough tissue left for us to then either do whole genome sequencing or even whole transcriptome sequencing, which may be required to build some of these assays.  I think the future lies in this idea of tumor uninformed assays because if we could go to a blood only or a plasma only approach using novel signatures like proteomics or methylation, I think that's where the future is. But we're still a little bit early in the discovery stages of those, as well as to come are the validation stages so that we can be confident that these blood-only assays may actually give us an answer.  So, with those three cautionary notes, I would say that optimism is still very high. I think ctDNA MRD is the right place to think about. We need to do this for our patients to better identify high-risk patients and to think about means to escalate treatment for them. Dr. Vamsi Velcheti: Yeah, I completely agree, and I think with all the changes and evolution of treatments in the management of early-stage lung cancer now with neoadjuvant and adjuvant, there's really a need for an escalation and de-escalation of therapies post-operatively. And I think it's a huge opportunity. I think we all could learn from our colorectal colleagues. I think they've done a really good job at actually doing prospective trials in this setting. I think we're kind of a little behind here.  Dr. Charu Aggarwal: I think in the metastatic setting there are ongoing trials to look at this exact question. How do you choose an appropriate first-line therapy, a monitor ctDNA at the six-week trial? It's being evaluated in a trial called the “Shedders” trial, where if patients are still ctDNA positive at six weeks, then you can escalate treatment because they haven't “cleared” their ctDNA. There has been a lot of research that has shown that lack of ctDNA clearance in the metastatic setting may be a poor prognostic factor. We and others have shown that if you do clear your ctDNA or if you have a reduction in ctDNA load overall, that that is directly related to both an improved progression-free survival and overall survival. This has been shown with both tissue informed and uninformed assays. So I think it's very clear that yes, you can track it. I think the question is: Can you apply that data to the early-stage setting? And that's an open research question. A lot of groups are looking at that and I think it's completely reasonable, especially to determine duration of therapy, to determine optimal timing, optimal timing of scans even. And I think these are just such interesting questions that will be answered in the future. Dr. Vamsi Velcheti: And also like a kind of early detection of resistance patterns that might inform early initiation of combination strategies. And I think it's a lot of opportunities I think yet to be explored. A lot of exciting things to come and I'm sure we'll kind of see more and more data in the next few years.  Dr. Aggarwal, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been a pleasure to have you on the podcast today. Hope to see you at ASCO. Dr. Charu Aggarwal: Thank you so much. This was great and I remain so excited by all of the possibilities to improve outcomes for our patients. Dr. Vamsi Velcheti: Thank you to all the listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:  Dr. Vamsidhar Velcheti  @VamsiVelcheti  @vamsivelcheti.bsky.social Dr. Charu Aggarwal @CharuAggarwalMD   Follow ASCO on social media:  @ASCO on X (formerly Twitter)  ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Vamsidhar Velcheti:  Honoraria: Glavanize Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Takeda, Janssen Oncology, Picture Health, Regeneron Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Charu Aggarwal: Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie Speakers' Bureau: AstraZeneca (an immediate family member) Research Funding (Inst): Merck Sharp & Dohme, AstraZeneca/MedImmune, Daiichi Sankyo/AstraZeneca, Lilly@Loxo, Candel Therapeutics  

In this episode of the Findaway Podcast, Dusty discusses the next step in his health journey—getting his biomarkers and testosterone levels checked. He explains that he partnered with HONE Health to undergo blood work, as he wants to better understand his hormone levels, especially after turning 40 and having two kids.Key Takeaways: • Why Check Biomarkers? • Hormones play a significant role in overall health, weight management, muscle building, and energy levels. • Factors like aging, parenting, and lifestyle changes can impact hormone levels, including testosterone. • Dusty has never had his testosterone levels checked before and wants to see if optimization is needed. • Concerns About Testing & Gimmicks • A follower raised concerns about health companies being gimmicky. • Dusty reassures that he is sharing his journey transparently, not promoting a product blindly. • He acknowledges skepticism but believes in the importance of getting hormone levels checked. • Testosterone & Its Effects • Lower testosterone can make weight management and muscle-building harder. • Hormonal imbalances can affect metabolism, energy, and how the body responds to food and exercise. • He mentions his wife's experience with PCOS, emphasizing how hormone imbalances can make weight loss more challenging. • The Testing Process • Bloodwork was done at home via a LabCorp professional. • He expects to receive results soon and will share them openly. • If levels are normal, he'll accept the natural shifts that come with age and life changes. If not, he'll explore potential solutions. • The Value of Sharing the Journey • Dusty reflects on how he originally didn't share his weight loss journey out of fear of failure. • He sees value in sharing the in-between moments rather than just before-and-after results. • He hopes this process helps others understand the importance of hormone health.Final Thoughts:Dusty is waiting for his test results and will share what he learns. Whether or not his testosterone needs optimization, he sees this as an opportunity to educate others on hormone health and how it impacts fitness and well-being.

What if you could take control of your health—before it's too late?

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.

My guest is Dr. Chris Palmer, M.D., a board-certified psychiatrist and professor at Harvard Medical School. He explains how specific nutrition, exercise, supplement-based, and other factors can improve mitochondrial health and thereby provide relief from adult and childhood ADHD, bipolar disorder, schizophrenia, and symptoms of autism. We discuss mitochondrial biology, whether vaccines can impact inflammation and mitochondrial health, and the potential ramifications. We also review creatine, methylene blue, and urolithin A, as well as the role of B vitamins and iron in treating depression. By the end of this episode, you will understand the powerful link between metabolic health and mental health, and the lifestyle, dietary, and other factors you can leverage to help overcome common mental health challenges and disorders. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Our Place: https://fromourplace.com/huberman LMNT: https://drinklmnt.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Dr. Chris Palmer 00:02:15 Integrating Metabolic, Mental & Physical Health; Childhood Trauma & Risk 00:10:46 Sponsors: Our Place & LMNT 00:13:44 Depression Causes, Molecule Model?, Neuroplasticity?; Metabolism 00:22:20 Mitochondrial Functions, Stress Response, Mental Health 00:31:09 Sponsors: AG1 & Eight Sleep 00:33:59 Mitochondrial Health & 6 Pillars of Lifestyle Medicine 00:39:38 Stimulants, Mitochondria, Dopamine; Alcohol 00:45:47 Nicotine; Substance Use, Metabolic Health & Disease 00:52:23 Children, Energy & Metabolic Function; Diseases of Aging & Mental Disorders 00:59:18 Sponsor: Function 01:01:06 Diet & Metabolism; Ultra-Processed Foods, Additives, GRAS 01:09:30 Rebellious Spirit, Ultra-Processed Foods & Food Industry Funding 01:19:14 Ketogenic Diet, Epilepsy, Schizophrenia, Bipolar 01:22:52 Ketogenic Diet, Fasting & Mitochondria; Gut Microbiome, Brain Metabolism 01:30:06 Low-Fat Diets; Tool: Occasional Fasts; Ketogenic Diet; Intermittent Fasting 01:38:40 Nutrition Research, Food Industry Lobbyists; Ultra-Processed Foods, Addiction 01:46:55 Creatine & Mitochondrial Health 01:52:34 Methylene Blue & Mitochondria; Serotonin Syndrome 02:02:58 Urolithin A, Mitochondria Function; Supplements & Appropriate Use 02:11:14 Vitamin Deficiencies, Iron Deficiency 02:16:06 Vitamin B12 & Folate Deficiency, Autoimmune Disorders 02:24:48 Mental Illness & Root Causes 02:29:02 Vaccines, Inflammation, Mitochondria, Autism 02:39:17 Neurodevelopmental Disorder Onset & Follow-Up 02:45:31 Vaccines, Autism, Future Research; Mother Obesity & Diabetes 02:51:23 Father Obesity & Autism; Poor Metabolic Health, Blood Biomarkers 02:56:44 Assessing Metabolic Health & Biomarkers; National Institutes of Health (NIH) 03:02:59 Future Directions, Bridging Mental & Physical Health 03:09:27 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

What's more important, subretinal or intraretinal fluid? What markers indicate inflammation and fibrosis?    Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002361?ecd=bdc_podcast_libsyn_mscpedu

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SJY865. CME/MOC/AAPA credit will be available until March 11, 2026.Dialing Up the Power of Alzheimer's Disease Biomarkers: A Practical Pathway to Earlier Diagnosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Identifying Patterns of Tobacco Use and Associated Cardiovascular Disease Risk Through Machine Learning Analysis of Urine Biomarkers

Nicole Rincon https://www.nicolerincon.comNicole's X https://x.com/NicoleRinconPARossignol Clinic https://rossignolmedicalcenter.comTACA Info: https://tacanow.org/wp-content/uploads/2019/10/F-H-2-Nicole-Rincon-Beginning-Biomed.pdfTACA Talks: https://www.nicolerincon.com/videosPublications https://rossignolmedicalcenter.com/articles-publications/#published-2024-2-articlesNicole Episode 1 https://www.youtube.com/watch?v=BBkdgwVfcZINicole Episode 2 https://www.youtube.com/watch?v=auLReV0DHkQDaylight Computer Company https://daylightcomputer.comuse "autism" in the discount code for $25 coupon.This is the future of tech.Chroma Light Therapy https://getchroma.couse "autism" for a 10% discount,***THIS IS NOT MEDICAL ADVICE***0:00 Nicole Rincon1:10 Daylight Computer Company; DC-15:33 Pre-pregnancy checks; Vitamin D8:37 MTHFR, Folate; Mitochondria; CPR, ESR, Inflammation11:12 GI; CSA; Bacteria, Fungus, Parasites, Calprotectin; Zonalin; MS & Proteus Mirabilis13:06 Organic Acid Test (OAT); Clostridia15:24 MTHFR; C677, 1298; Folinic Acid19:02 Folate's role in pregnancy and development; Critical info about types and duration22:35 Cholesterol; Maternal & Child; Speech & Communication25:06 Telepathy; Autism Rates26:40 Dysbiosis; PCOS29:30 Cholesterol ranges & symptoms; mood, irritability, cognition, aggression; Cortisol & Hormones37:02 Dysbiosis symptoms; Self-Injurious, Posturing41:08 Identifying symptoms in Non-Verbal; Self-Injurious45:08 Importance of Gut Health & Checks; Vitamin D, Electrical Efficiency & Biological Energy48:17 Autistics and pale skin; too many are pale; supplementing Vitamin D, K2; Brands51:00 Proprietary blends warning; abbreviated doses; Fungal overgrowth, Yeast55:49 "Binders;" Magnesium61:00 Fungal Overgrowth & Autism; OAT, Clostridia, C. diff, aggression, self-injurious; Antibiotics & Probiotics1:05:42 Telepathy Tapes, Autism, Water (Cytochrome C Oxidase), Coherence; Luc Montagier NOT Emilio Del Giudice; Distal Connections via Water and NOT axons; OutroX: https://x.com/rps47586Hopp: https://www.hopp.bio/fromthespectrumYT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

2024 ACC/AHA guideline update, including biomarker testing, MINS, and other consulting tips Master perioperative medicine! Learn when to hold ACE inhibitors, how to manage OSA without delaying surgery, and why "NPO after midnight" is outdated. We're joined by Dr. Avital O'Glasser, our Chief of Perioperative Medicine! Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case Preoperative Assessment & Consulting Tips Risk Calculators Frailty Pulmonary Considerations Cardiovascular Meds & BP Management NPO: Why Are We Still Doing This? Biomarkers & Postoperative Risk MINS Outro Credits Written and produced, show notes, cover art, CME, and infographics: Paul Wurtz MD.  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Molly Heublein MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Avital O'Glasser MD Disclosures Dr. O'Glasser reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures.  Sponsor: EZResus  Listeners of the Cribsiders and Curbsiders podcasts get access to a 2-month free trial,letting them use 100% of the features of the  For more information, www.ezresus.com/curbsiders and Use promo code Curbsiders Sponsor: Freed Visit Freed.ai and Usecode:CURB50 to get $50 off your first month when you subscribe. Sponsor: Mint Mobile Get 3 months of premium wireless service from Mint Mobile for $15 a month.Shop plans at mintmobile.com/curb

Mitochondria are the powerhouse of the cell, but their role in longevity and overall health goes far beyond energy production. When mitochondrial function declines, it contributes to aging, inflammation, and chronic disease. In this episode, I am excited to welcome back Dr. Elizabeth Yurth to break down why mitochondria are at the root of longevity, how to optimize mitochondrial function, and the best peptides, supplements, and lifestyle strategies to support cellular health.Dr. Elizabeth Yurth, MD, is a board-certified specialist in longevity, regenerative medicine, and orthopedics, as well as the co-founder and medical director of the Boulder Longevity Institute. She's a leading expert in peptide therapy, cellular medicine, and age-related disease prevention.- Intro (00:00 - 00:57)- Dr. Elizabeth Yurth's recent work in cellular medicine (00:57 - 04:34)- Why mitochondria are essential for energy and longevity (04:34 - 07:05)- Mitochondria and hormone production: The overlooked connection (07:05 - 08:20)- Mitochondrial dysfunction: The root cause of chronic disease (08:20 - 11:24)- How mitochondrial dysfunction leads to inflammation & oxidative stress (11:24 - 17:33)- Top signs & symptoms of mitochondrial dysfunction (17:33 - 24:31)- Environmental factors that damage mitochondria (toxins, stress, diet, etc.) (24:31 - 31:31)- Can we test for mitochondrial health? Biomarkers & lab tests (31:31 - 39:00)- How lifestyle impacts mitochondria: Fasting, exercise, red light therapy (39:00 - 45:15)- Best supplements for mitochondria: NAD, CoQ10, 1-MNA, creatine - and are NAD precursors like NMN & NR actually beneficial? (45:15 - 48:39)- Ketones & creatine: The ultimate mitochondrial enhancers (48:39 - 55:33)- Mitochondrial peptides: SS-31, Humanin, 5-Amino-1MQ & more (55:33 - 01:01:56)- How SS-31 repairs mitochondrial membranes & boosts energy (01:01:56 - 01:09:53)- The future of mitochondrial medicine: Mitochondrial uncouplers & new peptides (01:09:53 - 01:14:48)- Dr. Yurth's biggest lesson on longevity & cellular medicine (01:14:48 - 01:18:08)- Where to find Dr. Yurth & learn more about mitochondrial health (01:18:08 - 01:18:30)

Subscribe here or wherever you get your podcasts. This episode's guide is Santiago Brand, founder and director of MindLab Neuroscience Consulting in Singapore. He is a clinical and sports psychologist with expertise in qEEG, neurofeedback and biofeedback. He teaches and consults all over the world. Santiago gave a free webinar to the NRBS about EEG signs of trauma. In this podcast, we went a bit deeper into some of these biomarkers and how we they can be used to help individuals experiencing the consequences of trauma.Please rate us and leave reviews. It really helps get us to more listeners.This podcast is produced by the Northeast Region Biofeedback Society. NRBS is an organization for professionals, students, and everyone interested in neurofeedback, biofeedback, and whole body health.Learn more about Dr. Saul Rosenthal at advancedbehavioral.care.Contact us at healthybrain@nrbs.org.Our theme music is Catch It by Coma-MediaThe Healthy Brain Happy Body logo was designed by Alexandra VanDerlyke. Our heartfelt thanks to her and the rest of the team at Collectively Rooted.#biofeedback #neurofeedback #nrbs #trauma #PTSD #EEG #qEEG

In this special live episode of the Tick Boot Camp Podcast, we sit down with Dr. Tom Hight, a board-certified lipidologist and internal medicine specialist, at the International Lyme and Associated Diseases Society (ILADS) Conference. Dr. Hight has spent years pioneering cardiovascular risk reduction strategies, but an alarming trend caught his attention—patients with seemingly improving heart health were still experiencing worsening artery disease. His search for answers led him to Lyme disease and tick-borne illnesses as potential hidden drivers of cardiovascular risk. Key Takeaways Lyme Disease as a Cardiovascular Risk Factor Dr. Hight explains how chronic infections like Lyme disease contribute to inflammation in the endothelial cells, leading to increased risks of heart attacks, strokes, sudden cardiac death, and dementia. Endothelial Stress and Inflammation Chronic inflammation from Lyme disease can damage the arteries and accelerate heart disease, even in patients actively managing their cardiovascular health. Challenges in Diagnosis and Treatment Lyme disease is often overlooked in traditional cardiology, leaving many patients without proper treatment. Dr. Hight discusses the need for cross-disciplinary collaboration to better identify and manage these cases. Biomarkers and Early Detection New biomarkers are needed to detect Lyme-related inflammation in white blood cells, providing earlier intervention opportunities before significant cardiovascular damage occurs. Genetics vs. Lifestyle Factors While genetics play a role, Dr. Hight emphasizes that small, daily health choices can override genetic predispositions and dramatically reduce cardiovascular risk. Conclusion Dr. Hight's groundbreaking work at the intersection of Lyme disease and cardiovascular health highlights the urgent need for better diagnostic tools, interdisciplinary collaboration, and early intervention strategies. This conversation is a must-listen for both healthcare professionals and the Lyme community. Resources & Links Follow the latest ILADS updates: ILADS.org Learn more about Dr. Tom Hight and his work: CardioSound.com/about-us Stay connected with Tick Boot Camp: Website | Instagram | Facebook | YouTube | TikTok | Twitter (X)

Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year's meeting. --- This podcast is supported by: Photocure https://www.photocure.com/ --- SYNPOSIS First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice. --- TIMESTAMPS 00:00 - Introduction 09:20 - TALAPRO-2 Trial Insights 19:29 - Bladder Cancer: Immuno-Oncology Combinations and HER2 27:42 - NIAGARA and iNDUCT Trials 33:32 - Future Directions in Upper Tract Treatment 37:38 - Biomarkers in Kidney Cancer: KIM-1 46:43 - COSMIC-313: Triplet Therapy in Renal Cell Carcinoma 52:39 - Concluding Thoughts and Future Directions --- RESOURCES Photocure: https://www.photocure.com/

Dr. Brandon K.K. Fields speaks with Dr. Jennifer Holter-Chakrabarty about her groundbreaking research on fluorine-18 fluorothymidine (FLT) PET in the imaging of gastrointestinal graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. Together, they explore a potential future role for FLT-PET in detection of early and/or subclinical GVHD, which may serve to guide future treatment strategies for transplant patients in years to come. 18F-FLT PET and Blood-based Biomarkers for IdentifyingGastrointestinal Graft versus Host Disease after Allogeneic CellTransplantation. Holter-Chakrabarty and McNally et al. Radiology: Imaging Cancer 2025; 7(1):e240096. 

In this episode of the OHBM Neurosalience Podcast, host Peter Bandettini sits down with Dr. Simon Eickhoff, a leading clinician-scientist in brain mapping. As a panelist at the 2024 OHBM meeting in Seoul, Dr. Eickhoff brought fascinating insights—this conversation picks up where that discussion left off.Dr. Eickhoff, a professor and director at Heinrich-Heine University Düsseldorf and Forschungszentrum Jülich, works at the crossroads of neuroanatomy, data science, and brain medicine. His research focuses on understanding individual differences in brain organization, aging, and psychiatric disorders using machine learning and large-scale neuroimaging analysis.Topics include: - The challenges of deriving biomarkers and using fMRI in clinical settings - His experience leading the journal Human Brain Mapping & the evolving publishing landscape - The role of AI in psychiatry and the future of precision medicineJoin us for a deep dive into the innovations and challenges shaping neuroscience and brain imaging today!Episode ProducersXuqian Michelle LiOmer Faruk Gulban

Send us a textTestosterone therapy is more than just a trend—it's a crucial conversation about men's health, longevity, and quality of life. In this episode, Kevin is a guest on Matt Kaeberlein's Optispan Podcast, where we break down the science behind hormone health, exploring the real benefits and risks of testosterone therapy. From distinguishing primary vs. secondary hypogonadism to understanding the role of lifestyle in hormone optimization, we cover what every man needs to know. We'll also discuss how testosterone affects fertility, cancer risks, and cardiovascular health—and why finding the right provider makes all the difference. If you're considering hormone therapy or just want to optimize your health, this episode is a must-listen!Matt is a good friend, and valuable and trusted voice in longevity. You can also find Matt's podcast on Apple Podcasts here.TakeawaysTestosterone therapy is something everyone should consider.Men often delay seeking help for hormone issues.Regular testing of hormone levels is crucial after 40.Total testosterone levels alone do not provide a complete picture.Lifestyle changes can significantly impact testosterone levels.Clomiphene can help with secondary hypogonadism.Exogenous testosterone can affect fertility and hormone production.Proper dosing and administration of testosterone are essential.Monitoring for potential side effects is necessary.Finding a knowledgeable provider is key to effective treatment. Prime Health Associates

In this episode, Emma Sutherland hosts Christine Pope, a naturopath, nutritionist and homeopath, to explore strategies for healthy ageing. With Australia's ageing population on the rise, Christine highlights the role of diet, lifestyle, and targeted supplementation in extending healthspan, not just lifespan. Christine delves into the key biomarkers for ageing, such as insulin resistance, inflammation, and thyroid function. She discusses the nutrient deficiencies most common in older adults - particularly vitamin D, zinc, iron, magnesium, and iodine - and their impact on cognitive function, metabolism, and immunity. The conversation also covers the importance of protein intake, exercise for muscle preservation, and reducing the body's toxic burden. Christine shares insights from her training in the Bredesen Protocol for Alzheimer's and discusses how balancing blood sugar and optimising hormones can help prevent cognitive decline. This episode is packed with clinical pearls to help practitioners support healthy ageing and enhance patient outcomes. Find today's transcript and show notes here: https://www.bioceuticals.com.au/education/podcasts/healthy-ageing-more-than-just-extending-lifespan Covered in this episode: (00:55) Welcome Christine Pope (02:30) Practitioner's role in ageing (05:54) Lifespan vs healthspan (07:54) Ageing process (08:47) Biomarkers for ageing (12:41) Age related trends (16:54) Nutrient depletion (23:14) Iodine (26:14) Supplements for ageing (28:20) Insulin resistance (31:23) Toxicity (36:38) Exercise for longevity (38:24) Sarcopenia (41:00) Diet and multiple sclerosis (45:06) Mediterranean lifestyle (49:18) The Bredesen protocol (51:28) Final remarks Sign up for our monthly newsletter for the latest exclusive clinical tools, articles, and infographics: https://bit.ly/signup Find today's transcript and notes here: https://www.bioceuticals.com.au/education/podcasts/healthy-ageing-more-than-just-extending-lifespan Sign up for our monthly newsletter for the latest exclusive clinical tools, articles, and infographics: https://login.bioceuticals.com.au ***DISCLAIMER: The information provided on fx Medicine by BioCeuticals is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you learn here raises questions or concerns regarding your health.***

Parkinson's Disease has long been a clinical diagnosis. But recently, there have been proposals to redefine the disease based on biomarkers of alpha-synucleinopathy and dopaminergic dysfunction. A similar shift has already occurred in Alzheimer disease, with the “amyloid, tau, and neurodegeneration,” or ATN, classification system.    Our guest today, Michael Okun, is is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation. He co-authored an op-ed in JAMA last summer in JAMA arguing that there would be benefits to a biological definition of Parkinson's - but there would also be risks. He'll unpack both sides of this debate today with Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University. Series 6, Episode  5     Featuring: Guest: Dr. Michael Okun, is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation Interviewer: Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University Disclosures: None

When it comes to cancer, prevalence is increasing and there is still a lot we don't understand about the factors and causes of cancers. Many studies have clearly demonstrated the benefits of biomarker testing for cancer therapy. However, broadly speaking, roughly 30% of cancer patients are eligible for targeted therapies based on their tumor profile. And even when the biomarket is present, roughly 30% of the eligible patients respond to these treatments. We have a lot more to uncover. In the discussion you are about to hear, I spoke with Luka Ausec - an expert in the field of biology and computational science. He works as the Chief discovery officer at Genialis, RNA biomarker company which develops and validates clinically actionable biomarkers informed by the world's most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Luka oversees internal R&D and external partner projects, with the common goal of advancing therapeutic discovery through the rigorous application of data science. Luka's expertise in biology and computational disciplines makes him uniquely adept at innovating solutions at this nexus. He believes a successful discovery process is built on clear lines of communication and unwavering scientific integrity. In addition, Luka directs the implementation of Genialis' products. We discussed the current state of cancer research, role of computational science in drug discovery, clinical decision support development and response predictions development in the field of cancer. Read more on cancer research and digital health in our newsletter: https://substack.com/home/post/p-78204410 Website: www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/

Should you cut out alcohol after the Surgeon General's warning? We explore the literature and assess the risk. We also discuss what to do to reduce inflammation and manage cortisol, how to approach TikTok trends in skincare with your teens, and burnout at work. Timestamps:[1:48] Welcome[4:20] Discussion on alcohol and cancer risk[18:03] What are your best suggestions for lowering inflammation and high cortisol?[32:04] How do we talk to teens about making healthier choices when they're surrounded by Tik Tok trends?[42:18] I'd love to hear your opinion on beauty gadgets like red light face masks and new face specifically. [47:15] Has anyone ever quit a demanding job for a more enjoyable yet lower paying position to better manage stress and health? Episode Links:US Department of Health and Human Services: Alcohol and Cancer RiskPubMed: Alcohol, Aging, and the Stress ResponsePubMed: Dietary Protein and Changes in Biomarkers of Inflammation and Oxidative Stress Lumebox Red Light TherapySponsors:Go to http://mdlogichealth.com/mc  and use coupon code WELLFED for 10% off.Go to drinklmnt.com/wellfed and use code WELLFED to get a free 8-pack with any drink mix purchase!Go to organifi.com/wellfed and use code WELLFED for 20% off your order.Go to wellminerals.us/adrenal-stress-less/ and use code WELLFED to get 10% off your order.

Recent randomized trials, including EARLY TAVR, AVATAR, RECOVERY, and EVOLVED, suggest benefits of early aortic valve replacement (AVR) in asymptomatic severe aortic stenosis (AS). Early AVR reduces stroke, heart failure hospitalizations, and cardiovascular events, with a trend toward improved survival. The data support shifting from clinical surveillance to early intervention?

In today's episode of Barbell Shrugged the team digs into liver health, biomarkers, and optimization. The liver is a remarkable organ that performs numerous essential functions necessary for our overall well-being. Maintaining a healthy liver is vital, and understanding the role of biomarkers and optimization can help us achieve that goal. Our lifestyle choices significantly impact liver health. Unhealthy habits such as a processed food-heavy diet, excessive alcohol consumption, sedentary behavior, and chronic stress can damage the liver. On the other hand, adopting a healthy lifestyle with a balanced diet, regular exercise, stress management, and moderate alcohol consumption promotes optimal liver function. Biomarkers play a crucial role in assessing liver health. These measurable indicators, including liver enzymes like ALT and AST, bilirubin levels, and imaging techniques like ultrasound and MRI, provide valuable insights into liver function and overall health. By monitoring these biomarkers, healthcare professionals can identify inflammation, damage, and diseases such as fatty liver disease or viral hepatitis at an early stage, enabling timely intervention and prevention of further damage. Diet is a key factor in optimizing liver health. A nutrient-rich diet low in processed foods, added sugars, and unhealthy fats supports liver function. Foods such as leafy greens, cruciferous vegetables, fruits, whole grains, lean proteins, and healthy fats like avocados and olive oil provide necessary nutrients and antioxidants for the liver's detoxification processes. Supplements and herbs can also aid liver health. Milk thistle, containing silymarin with antioxidant and anti-inflammatory properties, has been used for centuries for its hepatoprotective effects. Other supplements like N-acetylcysteine (NAC) and turmeric have shown potential benefits in supporting liver health. It's important to consult with a healthcare professional before starting any new regimen to ensure personalized guidance. Alcohol consumption significantly impacts liver health. Excessive and chronic alcohol consumption leads to inflammation, fatty liver disease, and cirrhosis. Practicing responsible drinking by limiting alcohol intake and incorporating alcohol-free days is crucial for liver protection. Mental well-being is intertwined with liver health. Chronic stress and poor mental health can affect liver function. Implementing stress management techniques such as meditation, exercise, and seeking support from loved ones or professionals can reduce stress levels and support liver health. In conclusion, optimizing liver health through lifestyle modifications, biomarker monitoring, dietary adjustments, responsible alcohol consumption, and stress management is essential for overall well-being. Prioritizing a healthy lifestyle and seeking professional guidance can make a significant difference in supporting the liver's vital functions. Remember, a healthy liver leads to a healthier life. Anders Varner on Instagram Doug Larson on Instagram Travis Mash on Instagram Dan Garner on Instagram

Episode 184: Multiple Myeloma BasicsSub-Interns and future Drs. Di Tran and Jessica Avila explain the symptoms, work up and treatment of multiple myeloma. Written by Di Tran, MSIV, Ross University School of Medicine; Xiyuan Yang, MSIV, American University of the Caribbean. Comments by Jessica Avila, MSIV, American University of the Caribbean. Edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Di: Hi everyone, this is Di Tran, 4th year medical student from Ross university.  It's a pleasure to be back.  To be honest, this project is a part of teamwork of two medical students, myself and another 4th year, her name is XiYuan.  She came from the AUC. Unfortunately, due to personal matters she was unable to make it to the recording today which makes me feel really sad. Jessica: My name is Jessica Avila, MSIV, American University of the Caribbean.Di: The topic we will present today is Multiple Myeloma. Multiple myeloma is typically a rare disease and it's actually a type of blood cancer that affects plasma cells in the bone marrow.Jessica: Let's start with a case: A 66-year-old male comes to his family doctor for an annual health checkup. He is not in any acute distress but he reports that he has been feeling tired and weaker than usual for the last 3 months. He also noticed that he tends to bruise easily. He has a history of arthritis and chronic joint pain, but he thinks his back pain has gotten worse in the last couple of months. Upon checking his lab values, his family doctor found that he has a calcium level of 10.8 and a creatinine level of 1.2, which has increased from his baseline. Given all that information, what do you think his family doctor is suspecting? And what kind of tests she can order for further evaluation?Di: Those symptoms sound awfully familiar – are we talking about the CRAB? You know, the diagnostic criteria for Multiple Myeloma.Jessica: Exactly! Those are called “myeloma-defining events.” Do you remember what those are?Di: CRAB criteria comes in 4 flavors.  It's HYPERCALCEMIA with >1mg/dL, RENAL INSUFFICIENCY with serum creatinine >2mg/dL, ANEMIA with hemoglobin value 10% plasma cells, PLUS any one or more of the CRAB features, we can make the official diagnosis of multiple myeloma. Di:  Before we go deeper, let's back up a little bit and do a little background.  So, what do we know about the immunoglobulins, also known as antibodies? Back from years of studying from medical school, we know that the plasma cells are the ones that producing the antibodies that help fight infections.  There  are various kinds that come with various functions.  Each antibody is made up of 2 heavy chains and 2 light chains.  For heavy chains, we have A, D, E, G, M and for light chains we have Kappa and Lambda.Jessica: Usually, the 5 possible types of immunoglobulins for heavy chains would be written as IgG, IgA, IgD, IgE, and IgM.  And the most common type in the bloodstream is nonetheless the IgG. Di: What is multiple myeloma? In myeloma, all the abnormal plasma cells make the same type of antibody, the monoclonal antibody.  The cause of myeloma is unknown, but there are lots of studies and evidence that show a number of potential etiologies, including viral, genetic, and exposure to toxic chemicals, especially the Agent Orange, which is a chemical used as herbicide and defoliant. It was used as a chemical warfare by the U.S. military during the Vietnam War from 1961 to 1971.Jessica: We need to order some specific blood tests to see if there is elevated monoclonal proteins in the blood or urine. So, to begin with we'll need to take a very thorough history and physical exam. Next, we'll do labs, such as CBC, basic metabolic panel, calcium, serum beta-2 microglobulin, LDH, total protein, and some not so common tests: serum protein electrophoresis (SPEP), immunofixation of blood or urine (IFE), quantitative immunoglobulins (QIg), serum free light chain assay, and serum heavy/light chain ratio assay.If any of the results is abnormal, we should consider referring our patient to an oncologist.Di: Interesting! I read that Multiple Myeloma symptoms vary in different patients.  In fact, about 10-20% of patients with newly diagnosed myeloma do not have any symptoms at all.   Otherwise, classic symptomatic presentations are weakness, fatigue, increased bruising under the skin, reduced urine output, weakened bones that is likely prone to fractures, etc. And if multiple myeloma is highly suspected, a Bone Marrow biopsy should be done with testing for flow cytometry and fluorescent in situ hybridization (FISH). Actually, if any of the “Biomarkers of malignancy (SLIM)” is met we can also diagnose multiple myeloma even without the CRAB criteria. Jessica: The diagnosis is made if one or more of the following is found: >= 60% of clonal plasma cells on bone marrow biopsy, > 1 lytic bone lesion on MRI that is at least 5mm in size, or a biopsy confirmed plasmacytoma. Di: Imaging comes in at the final step especially if we able to find one or more sites of osteolytic bone destruction > 5mm on an MRI scan.Jessica: What if the bone marrow biopsy returns > 10% of monoclonal plasma cells, but our patient doesn't have either the CRAB or the Biomarker criteria? Di: That's actually a very good question, since Multiple Myeloma is part of a spectrum of plasma cell disorders. That's when smoldering myeloma comes into play. It is a precursor of active multiple myeloma. Smoldering myeloma is further categorized as high-risk or low-risk based on specific criteria.A less severe form is called Monoclonal Gammopathy of Undetermined Significance, or simply MGUS, with < 10% bone marrow involvement. Those are diagnoses we give once we rule out actual multiple myeloma, which are defined by the amount of M-protein in the serum.Jessica:  When to get started on treatment? Multiple Myeloma is on a spectrum of plasma cells proliferative disorders, starting from MGUS to Smoldering Myeloma, to Multiple Myeloma and to  Plasma Cell Leukemia.  Close supervision/active watching is enough for MGUS and low risk Smoldering Myeloma. But once it has progressed to high-risk smoldering myeloma or to active Multiple Myeloma, chemotherapy is usually required. Some situations may require emergent treatment to improve renal function, reduce hypercalcemia, and to prevent potential infections.Di: As of 2024, treatment of Multiple Myeloma comprises the Standard-of-Care approved by the FDA. In fact, the quadruple therapy is a combination of 4 different class of drugs that include a monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug, and a steroid. Jessica: They are Darzalex (daratumumab), Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone.  Other treatment plans for Multiple Myeloma include chemotherapy, immunotherapy, radiation therapy (for plasmacytomas) and stem cell transplants. The patient will also be on prophylaxis acyclovir and Bactrim while on chemotherapy. Sometimes anticoagulants are also considered because the chemo increases the risk of venous thromboembolic events.Di: Although the disease is incurable, but with the advancing of novel therapies and clinical trials patients with multiple myeloma are able to live longer.  Problem is the majority of patients diagnosed with Multiple Myeloma are older adults (>65), the risk of falling is adding to multiple complications of the disease itself, such as bone density loss, pain, neurological compromises, distress and weakness.  Palliative care may come in help at any point in time throughout the course of treatment but is most often needed at the very end of the course. Jessica, can you give us a conclusion for this episode?Jessica: Multiple Myeloma may not be the most common cancer, but we have to be aware of the symptoms and keep it in our differential diagnosis for patients with bone pain, easy bruising, persistent severe headaches, unexplained renal dysfunction, and remember the CRAB: HyperCalcemia, Renal impairment, Anemia and Bone lesions.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:International Myeloma Foundation. (n.d.). International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. https://www.myeloma.org/international-myeloma-working-group-imwg-criteria-diagnosis-multiple-myeloma Laubach, J. P. (2024, August 28). Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics). UpToDate. https://www.uptodate.com/contents/multiple-myeloma-symptoms-diagnosis-and-staging-beyond-the-basics.University of California San Francisco. (n.d.). About multiple myeloma. UCSF Helen Diller Family Comprehensive Cancer Center. https://cancer.ucsf.edu/research/multiple-myeloma/about Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

In this dual-release episode with Boundless Life and Miesha Tate’s Built for Growth, you’ll get to explore the cutting-edge strategies that top athletes and high-performers use to optimize their bodies and minds. This fascinating conversation dives into the power of comprehensive blood testing, hormonal balance, and genetic assessments for longevity and peak performance. You’ll also discover the latest in biohacking recovery tools—hyperbaric oxygen therapy, red light therapy, PEMF technology—and how they can accelerate recovery and enhance resilience. Whether you're an elite athlete or simply looking to take your health to the next level, this conversation is packed with practical, science-backed insights you can apply right away. Full show notes: https://bengreenfieldlife.com/tatepodcast Episode Sponsors: Force of Nature: Unlock 20% off your order at Force of Nature! Use code BEN at checkout for premium, responsibly sourced meats (minimum purchase of $189 required). Shop now: forceofnature.com/discount/BEN. Timeline Nutrition: Timeline is offering 10% off your first order of Mitopure—vegan softgels designed to provide the recommended dose of Urolithin A for boosted cellular health. Go to timelinenutrition.com/BEN and use code BEN to get 10% off your order. Analemma: To experience the science-backed power of coherent water for yourself, visit analemma-water.com and use code BENG for 10% off! Birch Living: Transform your sleep with a Birch mattress! Enjoy deep, restful nights with 20% off sitewide, plus 2 free Eco-Rest Pillows. Visit birchliving.com/bengreenfield to upgrade your sleep today! BEAM Minerals: If you want to up your mineral game, give BEAM Minerals a try. Go to beamminerals.com and use code BEN at checkout for 20% off your order. Lumen: Optimize your metabolism with Lumen's handheld metabolic coach! Gain personalized insights for better energy, weight management, fitness, and sleep. Lumen even adapts to hormonal changes to keep you feeling your best. Take the next step at lumen.me/GREENFIELD and get 20% off!See omnystudio.com/listener for privacy information.

Aging is a complex process, but have you ever wondered how it differs between men and women? In this week's episode of the Everything Epigenetics podcast, Sara Hägg, an Associate Professor at Karolinska Institutet, and I discuss the fascinating differences in biological aging between sexes. We explore how genetics, hormones, and lifestyle choices contribute to aging disparities and what that means for longevity, disease risk, and overall health.You'll learn about: - How Sara Hägg became interested in aging research and what led her to study sex-specific differences - The major ways men and women age differently at the genetic, molecular, and epigenetic levels - The role of hormones like estrogen and testosterone in shaping the aging process - Why women typically live longer than men and what factors influence this disparity - How stress, diet, and environmental exposures impact aging uniquely for men and women - The latest epigenetic research uncovering biological sex differences in aging - How precision medicine may help tailor aging interventions based on sex-specific needs - Biomarkers of aging and how they reveal crucial insights into longevity and healthspanChapters:00:00 – Introduction to Everything Epigenetics Podcast02:00 – Meet Sara Hägg: Her Background and Research Focus06:30 – What Inspired Her to Study Aging and Sex Differences10:00 – How Do Men and Women Age Differently?15:30 – The Role of Hormones: Estrogen, Testosterone, and Aging20:00 – Why Do Women Live Longer Than Men?26:00 – Cellular and Epigenetic Differences in Male vs. Female Aging30:00 – The Impact of Stress, Diet, and Environment on Aging36:00 – Age-Related Diseases: Which Are More Common in Men vs. Women?40:00 – How Biomarkers Help Predict Aging and Disease Risk45:00 – The Future of Precision Medicine in Aging50:00 – Misconceptions About How Men and Women Age55:00 – Surprising Findings from Sara Hägg's Research58:00 – Closing Thoughts & How to Connect with Sara HäggSupport the showWhere to Find Us:Instagram Twitter Facebook Follow us on:Apple Podcast Spotify YouTube Visit our website for more information and resources: everythingepigenetics.com Thank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how to harness this knowledge for your benefit.

Amy Attaway, MD, hosts the latest ATS Breathe Easy episode with former ATS President Monica Kraft, MD, and Asthma and Allergy Network's Chief Research Officer, De De Gardner, DrPH, discuss the benefits and challenges of biologics for asthma. What factors guide selection of a specific biologic for asthma? When should a patient transition from one biologic to another? 08:15 What does shared decision making mean?09:12 How often does a patient need to take a biologic? 12:58 What if you need to renew your biologic but you've stopped taking your inhaler?21:53 What's a strategy for combining biologics for asthma?

Intro: Bitter cold and snow, stupid drivers and having a fun activity during winter months.10:28: Biology and weather acclimation.13:12: Leia is not molting and Lewis and Clark are not as exploratory (Chickens).15:57: Bari Weiss with Bryan Johnson, Blueprint and living forever.23:23: Where Molly thinks he's dangerous and modern day Tower of Babel.25:40: “We are building god in technology and super-intelligence,” and the great deception.27:52: Biomarkers and background.31:19: His meaning of “Don't Die,” “Living for tomorrow and living forever are identical concepts.”34:41: “As human species we accept our inevitable decay and death. I want to argue that the opposite should be true.”38:52: A scary outcome: “Don't be a hero, don't sacrifice, don't die.”41:00: Dehumanizing the idea of being human.45:43: Naturally, the tie to Ecclesiastes49:54: We can take it with us: thoughts from The Supper of the Lamb.53:24: Forest Bathing is really hunting.56:17: The best meals, the best sex, the experience in nature is good for the body and soul.1:00:18: Our son, bird flu and a nebulizer1:01:30: Show close. Too Busy to Flush Telegram GroupSend us a PostcardCanavoxThe Milk Frother Currently Being Tested!Pique Tea - Referral Link (it's super-delicious and healthy)Ledger Hardware Wallet - Referral Link (store your crypto securely!)

Could the right form of a single vitamin be the difference between thriving and barely surviving? In this Part 2 conversation, human biologist and longevity expert Gary Brecka reveals the #1 overlooked factor that's wrecking your health: methylation—your body's ability to convert nutrients into fuel. If this process fails, your hormones, energy, and even mental health take a nosedive. Gary and Dave dive deep into the real cause of anxiety, ADHD, and mood disorders, the hidden genetic reason why diets fail, and why Big Pharma isn't talking about this critical health breakthrough. Are you unknowingly setting yourself up for disease? What's the simple fix that can reverse anxiety, gut problems, and even prevent genetic disease? And why is your doctor ignoring one of the biggest markers of longevity? What You'll Learn: • The MTHFR gene mutation—and why it's quietly affecting millions • Anxiety, ADHD, and depression—why these disorders start in your cells, not your brain • The gut-brain connection—how your microbiome controls your mood • Why your “healthy diet” might be hurting you (and what to eat instead) • How nutrient deficiencies are passed from mother to child—and how to stop it • The truth about homocysteine—the blood marker that could predict your lifespan • Why most people are living at 50% capacity—and how to get your energy back Resources: • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Gary Brecka's Website: https://bit.ly/4hlfyti • Gary Brecka's YouTube: https://bit.ly/3E3Aaba • Gary Brecka's Instagram: https://bit.ly/3PNsgFe • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com • The Mold Movie!: https://moldymovie.com/ SPONSORS: -BON CHARGE | Go to https://boncharge.com/ and use coupon code DAVE to save 15%. -Qualia | Go to https://www.qualialife.com/dave15 to get an additional 15% off subscriptions. Timestamps: • 00:00 Trailer • 00:31 What Is Methylation? • 01:37 MTHFR, Folate & Your Health • 04:17 How Methylation Affects Disease • 06:41 Nutrient Deficiencies & Health Risks • 07:09 Why Blood Work Matters • 11:44 Homocysteine & Heart Health • 21:37 Catecholamines & Anxiety • 34:28 The Link Between Nutrients & Mood • 34:48 How Catecholamine Ratios Affect Mental Health • 35:39 Personal Health Struggles & Lessons • 36:25 The Role of Methylation in Wellness • 37:57 Methylation & Relationship Dynamics • 39:49 Hidden Dangers of Mold Toxicity • 52:55 Hydrogen Water for Health • 01:01:19 Mitochondria's Role in Longevity • 01:02:23 Final Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Things are changing quickly in the Alzheimer's space. We now have biomarkers that can reasonably approximate the degree of amyloid build-up in the brain with a simple blood test.  We have two new FDA-approved medications that reduce that amyloid buildup and modestly slow down the progression of the disease.  So, the question becomes, what, if anything, should we do differently in the primary care setting to diagnose the disease? On today's podcast, we've invited Nathaniel Chin back to the GeriPal podcast to talk about what primary care needs to manage this new world of Alzheimer's disease effectively.  Nate is a geriatrician and clinician-scientist at the University of Wisconsin, as well as the host of the Wisconsin ADRC's podcast, "Dementia Matters." In each bi-weekly episode, he interviews Alzheimer's disease experts about research advances and caregiver strategies. Nate also wrote a NEJM piece last year on “Alzheimer's Disease, Biomarkers, and mAbs — What Does Primary Care Need?” We address the following questions with Nate: Has anything changed for the primary care doctor when diagnosing Alzheimer's?  How should we screen for cognitive impairment? Does a good history matter anymore? What's the role of assessing function? What do we do with those who have only subjective cognitive complaints? Can't we skip all this and just send some blood-based biomarkers? What is the role of the amyloid antibody treatments? Lastly, take a look at the following if you want to take a deeper dive into some of the other articles and podcasts we discuss: First, two competing definitions of what is Alzheimer's: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group (IWG) Recommendation Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care Podcasts we mentioned Prevention of Dementia: A Podcast with Kristine Yaffe Screening for Dementia: A Podcast with Anna Chodos, Joseph Gaugler and Soo Borson

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned expert in clinical lipidology and a previous guest on The Drive. In this episode, Tom explores the foundations of atherosclerosis and why atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide for both men and women. He examines how the disease develops from a pathological perspective and discusses key risk factors, including often-overlooked contributors such as insulin resistance and chronic kidney disease. He breaks down the complexities of cholesterol and lipoproteins—including LDL, VLDL, IDL, and HDL—with an in-depth discussion on the critical role of apolipoprotein B (apoB) in the development of atherosclerosis. Additionally, he covers the importance of testing various biomarkers, the impact of nutrition on lipid levels, and the vital role of cholesterol in brain health, including how cholesterol is synthesized and managed in the brain, how it differs from cholesterol regulation in the rest of the body, and how pharmacological interventions can influence brain cholesterol metabolism. We discuss: Defining atherosclerotic cardiovascular disease (ASCVD): development, risks, and physiological impact [2:45]; The pathogenesis of ASCVD: the silent development over decades, and the importance of early detection for prevention of adverse outcomes [10:45]; Risk factors versus risk markers for ASCVD, and how insulin resistance and chronic kidney disease contribute to atherosclerosis [17:30]; How hyperinsulinemia elevates cardiovascular risk [24:00]; How apoB-containing lipoproteins contribute to atherosclerosis, and why measuring apoB is a superior indicator of cardiovascular risk compared to LDL cholesterol [29:45]; The challenges of detecting early-stage atherosclerosis before calcification appears [46:15]; Lp(a): structure, genetic basis, and significant risks associated with elevated Lp(a) [55:30]; How aging and lifestyle factors contribute to rising apoB and LDL cholesterol levels, and the lifestyle changes that can lower it [59:45]; How elevated triglycerides, driven by insulin resistance, increase apoB particle concentration and promote atherosclerosis [1:08:00]; How LDL particle size, remnant lipoproteins, Lp(a), and non-HDL cholesterol contribute to cardiovascular risk beyond apoB levels [1:21:45]; The limitations of using HDL cholesterol as a marker for heart health [1:29:00]; The critical role of cholesterol in brain function and how the brain manages its cholesterol supply [1:36:30]; The impact of ApoE genotype on brain health and Alzheimer's disease risk [1:46:00]; How the brain manages cholesterol through specialized pathways, and biomarkers to track cholesterol health of the brain [1:50:30]; How statins might affect brain cholesterol synthesis and cognitive function, and alternative lipid-lowering strategies for high-risk individuals [1:57:30]; Exciting advancements in therapeutics, diagnostics, and biomarkers coming in the next few years [2:09:30]; Recent consensus statements on apoB and Lp(a) from the National Lipid Association (NLA) [2:12:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this episode, John Thomson Smith, a physician executive, explores the science of longevity and the critical role of healthspan in living a vibrant life. They discuss how tracking key biomarkers, such as VO2 max, heart rate variability, and telomere length, can empower individuals and clinicians to make data-driven decisions that enhance both daily vitality and long-term health. Whether you're a health care professional or a patient seeking to optimize your well-being, this conversation offers actionable insights into the journey toward a thriving healthspan. John Thomson Smith is a physician executive. He discusses the KevinMD article, "Biomarkers: How to manage your body's KPIs for longevity." Our presenting sponsor is DAX Copilot by Microsoft. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of patient care. Microsoft is committed to helping clinicians restore the balance with DAX Copilot, an AI-powered, voice-enabled solution that automates clinical documentation and workflows. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Help restore your work-life balance with DAX Copilot, your AI assistant for automated clinical documentation and workflows. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus